Compare DFIN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | DRTS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 991.6M | 978.2M |
| IPO Year | 2017 | N/A |
| Metric | DFIN | DRTS |
|---|---|---|
| Price | $38.69 | $10.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $61.50 | $8.67 |
| AVG Volume (30 Days) | 332.3K | ★ 975.6K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $963,000,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $3.87 | $699.98 |
| P/E Ratio | $31.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.07 | $2.81 |
| 52 Week High | $66.25 | $11.62 |
| Indicator | DFIN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 58.06 |
| Support Level | $37.11 | $6.59 |
| Resistance Level | $50.68 | $11.62 |
| Average True Range (ATR) | 1.51 | 1.01 |
| MACD | 0.29 | -0.12 |
| Stochastic Oscillator | 33.78 | 66.67 |
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.